Results 311 to 320 of about 3,443,356 (396)

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib. [PDF]

J Transl Med
Dewulf J, Navarro L, Dumauthioz N, Berdal M, Nagachinta S, Gaspariunaite V, Pombo Antunes AR, Lahoutte T, Massa S, Devoogdt N, D'Huyvetter M.   +10 more
europepmc   +1 more source

Author response: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen, Meixiao Long, Yi Fan, Kathleen T. Montone, János L. Tanyi, Sarah H Kim, Omid Tavana, Robert H. Vonderheide, Ho Man Chan, Susan M. Domchek, Xiaowen Hu, Lin Zhang   +20 more
openalex   +1 more source

Dual inhibition of ATR and PARP reverses acquired PARP inhibitor resistance in triple negative breast cancer. [PDF]

Discov Oncol
Guney Eskiler G, Haciefendi A, Ozdemir K, Bilir C.   +3 more
europepmc   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, Volume 173, Issue 3, Page 1334-1342, June 2026.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

RAGE Re‐Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Cancer cachexia (CC) is a highly debilitating syndrome characterized by loss of body and muscle weight affecting most advanced cancer patients. The receptor for advanced glycation end‐products (RAGE) is expressed by several cell types and sustains the inflammatory response in acute and chronic diseases. Total ablation of RAGE (Ager−/
Sara Chiappalupi, Giulia Gentili, Laura Salvadori, Martina Paiella, Marcello Manfredi, Vittoria Federica Borrini, Kaamashri Mangar, Ann Marie Schmidt, Maurizio Muscaritoli, Francesca Riuzzi, Guglielmo Sorci   +10 more
wiley   +1 more source

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. [PDF]

Sci Rep
Suresh S, McPherson L, Ford JM.
europepmc   +1 more source

Fatty Acid Metabolism in Health and Cancer: From Fundamental Mechanisms to Therapeutic Application

MedComm, Volume 7, Issue 6, June 2026.
The modulation of the TME by fatty acid metabolism primarily occurs through four key pathways: inflammation regulation, signal transduction, translation to TME, and oxidative stress. ABSTRACT Fatty acid metabolism (FAM) plays a vital role in maintaining health by supporting energy production, cellular structure, and signaling processes.
Na Hang, Runkang Zhao, Fan Zhang, Dandan Guo, Qing Li, Zhijun Shen, Ruiqing Gao, Chenyu Gao, Zhao Xie, Sentao Fu, Peng Luo, Bufu Tang, Ling Wang   +12 more
wiley   +1 more source

Comprehensive genomic profiling for homologous recombination deficiency guides PARP inhibitor therapy recommendations in ovarian cancer. [PDF]

Pathol Oncol Res
Inci A, Witzel I, Moch H, Rahmani-Khajouei S, Zoche M, Samartzis EP.   +5 more
europepmc   +1 more source

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source